New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For MRK;PFE;GSK;JNJ;BMY;NVS;SHPG;ABT;CELG;SNY From The Last 14 Days
Check below for free stories on MRK;PFE;GSK;JNJ;BMY;NVS;SHPG;ABT;CELG;SNY the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | 4 | all recent news | >>
September 22, 2014
07:50 EDTJNJDoctors continue to use morcellators despite FDA warning, J&J halt, WSJ says
Subscribe for More Information
07:21 EDTBMY, CELG, SNY, GSKEBD Group to hold a conference
Subscribe for More Information
07:07 EDTJNJSynageva appoints Robert Bazemore as COO
Synageva announced the appointment of Robert Bazemore as Chief Operating Officer. Bazemore will oversee the planned global commercial launch of the company's lead program, sebelipase alfa for LAL Deficiency, and will have responsibility for the company's global commercial, market access and medical affairs operations. Bazemore last served at Johnson & Johnson (JNJ) in varoius roles including Vice President, Ethicon New Growth Platforms and President of Janssen Biotech, a part of the Janssen Pharmaceutical Companies of Johnson & Johnson.
07:06 EDTABTAbbott price target raised to $48 from $44 at RBC Capital
Subscribe for More Information
06:51 EDTMRKMerck to host conference call
Subscribe for More Information
05:27 EDTGSKGlaxoSmithKline upgraded to Buy from Neutral at Goldman
Subscribe for More Information
September 19, 2014
16:00 EDTPFEOptions Update; September 19, 2014
Subscribe for More Information
11:25 EDTABTSenators bring bill requiring companies to settle before inverting
U.S. Senators Sherrod Brown and Dick Durbin announced new legislation requiring corporations to "Pay What You Owe Before You Go" – settling their U.S. tax bill before relocating to a foreign country. "Everyone knows that before you leave a restaurant you have to settle your tab," Brown said. "Corporations shouldn’t get to play by different rules. While it is critical that we reach a long-term solution that reforms our international corporate tax code by implementing a global minimum tax and reducing the statutory tax rate, this bill is an immediate, commonsense measure to ensure businesses settle up before leaving the U.S." Among the deals or possible transactions that involve inversion are Mylan's (MYL) acquisition of Abbott (ABT), Medtronic's (MDT) acquisition of Covidien (COV) and Valeant's (VRX) proposed takeover of Allergan (AGN).
10:07 EDTPFEHigh option volume stocks
Subscribe for More Information
05:58 EDTGSKGlaxoSmithKline to pay GBP 297M fine to Chinese government
Subscribe for More Information
September 18, 2014
08:48 EDTMRKNeogen's dairy genomic program to be marketed by Merck
Subscribe for More Information
September 17, 2014
14:57 EDTGSKProsensa announces commencement of re-dosing of drisapersen
Subscribe for More Information
09:33 EDTMRKMerck announced positive results from Phase 3 data for omarigliptin
Subscribe for More Information
08:36 EDTJNJJanssen-Cilag announces results from post-hoc canagliflozin analysis
Subscribe for More Information
08:31 EDTMRKMerck, Sun Pharma enter into licensing agreement for Tildrakizumab
Merck and Sun Pharmaceutical Industries, through their respective subsidiaries,announced an exclusive worldwide licensing agreement for Merck’s investigational therapeutic antibody candidate, tildrakizumab, which is currently being evaluated in Phase 3 registration trials for the treatment of chronic plaque psoriasis, a skin ailment. Under terms of the agreement, Sun Pharma will acquire worldwide rights to tildrakizumab for use in all human indications from Merck in exchange for an upfront payment of $80M. Merck will continue all clinical development and regulatory activities, which will be funded by Sun Pharma. Upon product approval, Sun Pharma will be responsible for regulatory activities, including subsequent submissions, pharmacovigilance, post approval studies, manufacturing and commercialization of the approved product. Merck is eligible to receive undisclosed payments associated with regulatory and sales milestones, as well as tiered royalties ranging from mid-single digit through teen percentage rates on sales. The transaction is subject to customary closing conditions, including the requirements under the Hart Scott-Rodino Antitrust Improvements Act.
08:12 EDTJNJJanssen-Cilag announces results from Phase 3 Invokana trial
Subscribe for More Information
07:43 EDTPFE, BMY, SHPGBofA/Merrill to hold a conference
Subscribe for More Information
07:39 EDTGSKMorningstar to hold a conference
Management Behind the Moat Conference to be held in Chicago on September 17-18.
07:00 EDTCELGConcert Pharmaceuticals announces initiation of CTP-730 Phase 1 trial
Subscribe for More Information
06:18 EDTSNYSanofi, MyoKardia announce collaboration
Subscribe for More Information
September 16, 2014
11:51 EDTSHPG, PFE, ABTOECD looks to close tax loopholes with new proposals
Subscribe for More Information
07:33 EDTGSK, SNYMylan initiates Phase III clinical trials for Advair Diskus and Lantus
Mylan (MYL) announced it is initiating Phase III clinical trials for its generic version of GlaxoSmithKline's (GKS) Advair Diskus and its insulin analog to Sanofi's (SNY) Lantus. In October Mylan will commence a Phase III clinical trial to evaluate the equivalence of its product to Advair Diskus when administered by inhalation in adult asthma patients.
07:31 EDTGSK, MRK, JNJ, NVSEuropean Association for Study of Diabetes to hold annual meeting
50th Annual Meeting of EASD to be held in Vienna, Austria on September 15-19.
07:25 EDTMRKMerck price target raised to $72 from $62 at SunTrust
After meeting with Merck's CEO and head of clinical development, SunTrust increased its price target on the company as the firm thinks that it is ideally positioned across five of the fastest growing therapeutic classes. The firm believes that the company's EPS growth rates from 2015-2020 will be three percentage points above Street estimates, while it has a first-mover advantage in oncology. It keeps a Buy rating on the shares.
07:19 EDTPFECompanies' share buybacks at fasttest clip since 2007, WSJ reports
Companies are buying back their own shares at its fastest pace since the financial crisis to fuel a stock rally, reports the Wall Street Journal. According to Birinyi Associates, companies have bought back $338.3B of stock in 1H14, the most since 2007. Citing an analysis by Barclays, companies with the largest buyback programs by dollar value have outperformed the broader market by 20% since 2008. Reference Link
06:00 EDTBMYBristol-Myers announces Health Canada approval of Yervoy
Subscribe for More Information
September 15, 2014
16:10 EDTGSKFive Prime announces option exercise by GlaxoSmithKline to obtain license
Subscribe for More Information
13:30 EDTMRKMerck announces data from pivotal Phase 3 study for odanacatib
Merck announced data from the pivotal Phase 3 fracture outcomes study for odanacatib in postmenopausal women with osteoporosis. Odanacatib is Merck’s investigational once-weekly cathepsin K inhibitor. In the Long-Term Odanacatib Fracture Trial, odanacatib met its primary endpoints and significantly reduced the risk of osteoporotic hip, spine and non-vertebral fractures compared with placebo. The rates of adverse events overall in LOFT were generally balanced between patients taking odanacatib and placebo. Adjudicated events of morphea-like skin lesions and atypical femoral fractures occurred more often in the odanacatib group than in the placebo group. Adjudicated major adverse cardiovascular events were generally balanced overall between the treatment groups. There were numerically more adjudicated stroke events with odanacatib than with placebo.
10:55 EDTSHPGRegulators to determine AbbVie, Shire deal by next month, Reuters says
Subscribe for More Information
09:32 EDTABTAbbott initiates ABSORB IV trial
Abbott announced the start of the ABSORB IV clinical trial, which will test whether its Absorb Bioresorbable Vascular Scaffold is more cost-effective and offers a higher quality of life than a permanent, metallic drug eluting stent. Unlike a metallic stent, Absorb completely dissolves over time after doing its job. ABSORB IV is designed to enroll approximately 3K people with coronary artery disease, mostly in the U.S. The ABSORB IV trial is designed to confirm these novel findings that treatment with the Absorb device can help provide people with heart disease a higher quality of life after a heart stent procedure. The data from the ABSORB IV trial will be combined with the data from the ABSORB III trial to create a population of more than 5K people studied in the U.S. This data set, which is the largest of its kind for bioresorbable heart devices, provides an opportunity to evaluate the performance of Absorb compared to the current standard of a metallic drug eluting stent across a number of measures, including the broader health economic impact of this innovative therapy.
09:25 EDTPFEJPMorgan biotech analysts hold an analyst/industry conference call
Analysts assess Pfizer's M&A options on an Analyst/Industry conference call to be held on September 15 at 10 am.
08:01 EDTSHPGShire announces FDA acceptance for filing of sNDA for Vyvanse
Subscribe for More Information
07:45 EDTABTCardiovascular Research Foundation to hold a conference
Transcatheter Cardiovascular Therapeutics: TCT 2014 to be held in Washington, D.C. on September 13-17 with some presentations being webcasted. Webcast Link
07:27 EDTJNJ, CELG, GSK, PFE, NVSIBC Life Sciences to hold a conference
Subscribe for More Information
07:27 EDTPFEPfizer acquisition could drive shares higher, says JPMorgan
Subscribe for More Information
07:21 EDTNVSHeart Failure Society of America to hold annual meeting
Subscribe for More Information
September 14, 2014
13:32 EDTPFEPfizer shares look cheap, Barron's says
Subscribe for More Information
13:30 EDTABTAbbott announces positive one-year clinical results from ABSORB II
Subscribe for More Information
September 12, 2014
10:32 EDTPFEPfizer CEO says company still open to inversion deal, FT says
Pfizer (PFE) CEO Ian Read said U.S. rhetoric against tax inversions has been "political theater" ahead of midterm elections and made clear that his company is still open to a potential tax-saving acquisition, according to Financial Times, which added Read's comment about not being “held hostage” over price would likely be read as a signal the company might look elsewhere after being rebuffed by AstraZeneca (AZN). The Fly notes that Bloomberg previously reported, citing people familiar with the matter, that Pfizer is looking at targets other than AstraZeneca, including Actavis (ACT). Shares of Actavis trading in New York are up 2% this morning. Reference Link
10:04 EDTSNYSanofi unit granted orphan status for treatment of Gaucher disease
Subscribe for More Information
05:18 EDTNVSNovartis announces new data confirms high efficacy of Gilenya in achieving NEDA
Novartis announced new analyses presented at the Joint ACTRIMS-ECTRIMS Meeting in Boston, USA, which confirmed the high efficacy of Gilenya in achieving 'no evidence of disease activity', or NEDA, in people with relapsing-remitting multiple sclerosis, or RRMS, across four key disease measures - relapses, MRI lesions, brain shrinkage and disability progression. Specifically, patients taking Gilenya had a more than four-times greater likelihood of achieving NEDA across these four key measures. NEDA is currently defined as having no relapses, MRI lesions and disability progression. These new analyses from the phase III FREEDOMS and FREEDOMS II trials reinforce the value of including brain shrinkage to the definition of NEDA. The inclusion of brain shrinkage into the NEDA definition would allow physicians to obtain a more complete assessment of a patient's disease, including the underlying damage in MS.
September 11, 2014
13:41 EDTABTAbbott announces new $3B share repurchase program
Subscribe for More Information
07:11 EDTJNJMedivation price target raised to $112 from $89 at Stifel
Subscribe for More Information
05:27 EDTSNYGenzyme announces positive interim results from Lemtrada extension study
Subscribe for More Information
September 10, 2014
16:00 EDTMRKOptions Update; September 10, 2014
Subscribe for More Information
10:14 EDTJNJJohnson & Johnson says off to 'very good start' this year
Subscribe for More Information
09:58 EDTGSKGlaxoSmithKline has a conference call hosted by JPMorgan
Subscribe for More Information
08:37 EDTSHPGMedgenics appoints Scott Applebaum as Chief Legal Officer
Subscribe for More Information
07:09 EDTSNYAmericas Committee for Treatment & Research in MS to hold a meeting
Subscribe for More Information
07:06 EDTSHPGSangamo plans to submit IND application for hemophilia B in 2Q15
Sangamo BioSciences (SGMO) plans to submit an Investigational New Drug application for the treatment of hemophilia B in Q2 2015. This program, partnered with Shire (SHPG), is the first therapeutic application of Sangamo's zinc finger nuclease-mediated In Vivo Protein Replacement Platform. Sangamo is developing the IVPRP as a generally applicable strategy to provide a one-time, permanent genetic cure for monogenic diseases that are currently managed by protein replacement therapy, which involves costly repeat infusions over the lifetime of the patient.
05:17 EDTNVSNovartis Gilenya data confirms reducing brain shrinkage matter for MS patients
Subscribe for More Information
September 9, 2014
07:55 EDTNVSOphthotech earlier than expected Novartis payment positive, says Oppenheimer
After Ophthotech (OPHT) received a $50M Phase 3 enrollment payment from Novartis (NVS) earlier than expected, Oppenheimer thinks the payment highlights an underappreciated stock driver for Opthotech, and demonstrates that recent suggestions of Phase 3 enrollment timelines possibly slipping are unwarranted. The firm believes the company is executing well on the Fovista Phase 3 program and keeps an Outperform rating on the stock.
07:51 EDTCELGNICE says Abraxane price not justified by limited benefit in pancreatic cancer
Subscribe for More Information
06:42 EDTABTLew expects to make decision on combating inversion deals soon, NY Times reports
Subscribe for More Information
06:25 EDTGSKDocuments show DOJ probed GSK China unit in 2012, Reuters says
Internal documents revealed that a U.S. anti-bribery investigation into GlaxoSmithKline (GSK) touched on the firm's Chinese consumer healthcare division two years ago, which infers that the company's compliance issues in the country could be broader than initially discovered, according to Reuters, citing the documents. Reference Link
September 8, 2014
16:00 EDTMRKOptions Update; September 8, 2014
Subscribe for More Information
14:16 EDTSNYSanofi announces FDA approval of Menactra vaccine
Subscribe for More Information
09:27 EDTNVSLeerink biotech analyst holds a luncheon meeting with a conference call
Biotech Analyst Schwartz provides an update on key trends and controversies for marketed MS therapies and discusses new data presented at ACTRIMS-ECTRIMS at a Luncheon Meeting with an Analyst/Industry conference call to be held in Boston on September 11 at 12:15 pm.
08:48 EDTGSKGilead announces AMBITION study results in collaboration with Glaxo
Subscribe for More Information
08:38 EDTNVSMerus Labs acquires Sintrom from Novartis
Subscribe for More Information
07:33 EDTNVSOphthotech achieves $50M milestone under ex-agreement with Novartis for Fovista
Subscribe for More Information
07:26 EDTCELGMorgan Stanley to hold a conference
Subscribe for More Information
07:15 EDTPFEIBC Life Sciences to hold a conference
10th Annual Cell Line Development & Engineering Conference to be held in Berkeley, California on September 8-10.
<< 1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use